Reproducibility of serologic assays for influenza virus A (H5N1). - Wikidata - wikimedia - TriplyDB

Reproducibility of serologic assays for influenza virus A (H5N1).

Reproducibility of serologic assays for influenza virus A (H5N1).

http://www.wikidata.org/entity/Q33628688

about

Assessment of serosurveys for H5N1 Current Approaches for Diagnosis of Influenza Virus Infections in Humans Influenza Vaccination Strategies: Comparing Inactivated and Live Attenuated Influenza Vaccines H5N1 vaccines in humans Weighing serological evidence of human exposure to animal influenza viruses - a literature review Safety and immunogenicity of AS03B adjuvanted split virion versus non-adjuvanted whole virion H1N1 influenza vaccine in UK children aged 6 months-12 years: open label, randomised, parallel group, multicentre study Influence of body condition on influenza A virus infection in mallard ducks: experimental infection data A cell culture-derived MF59-adjuvanted pandemic A/H7N9 vaccine is immunogenic in adults.Estimating age-specific cumulative incidence for the 2009 influenza pandemic: a meta-analysis of A(H1N1)pdm09 serological studies from 19 countries.Seroprevalence to influenza A(H1N1) 2009 virus--where are we?Long-term outcome of the humoral and cellular immune response of an H5N1 adjuvanted influenza vaccine in elderly persons: 2-year follow-up of a randomised open-label study.The safety and immunogenicity of a MF59-adjuvanted H5N1 prepandemic influenza vaccine in healthy adults primed with homologous or heterologous H5N1 vaccines: an observational study Pseudotype-based neutralization assays for influenza: a systematic analysis.Competitive detection of influenza neutralizing antibodies using a novel bivalent fluorescence-based microneutralization assay (BiFMA).Comparability of neuraminidase inhibition antibody titers measured by enzyme-linked lectin assay (ELLA) for the analysis of influenza vaccine immunogenicity Influenza immunology evaluation and correlates of protection: a focus on vaccines.CONSISE statement on the reporting of Seroepidemiologic Studies for influenza (ROSES-I statement): an extension of the STROBE statement.Flexible label-free quantitative assay for antibodies to influenza virus hemagglutinins A Formulated TLR7/8 Agonist is a Flexible, Highly Potent and Effective Adjuvant for Pandemic Influenza Vaccines.Immunogenicity profile of a 3.75-μg hemagglutinin pandemic rH5N1 split virion AS03A-adjuvanted vaccine in elderly persons: a randomized trial.Sensitivity and specificity of serologic assays for detection of human infection with 2009 pandemic H1N1 virus in U.S. populations.Prevalence of antibodies to 2009 pandemic influenza A (H1N1) virus in German adult population in pre- and post-pandemic period.Post-pandemic seroprevalence of pandemic influenza A (H1N1) 2009 infection (swine flu) among children <18 years in Germany.Characterization and long-term persistence of immune response following two doses of an AS03A-adjuvanted H1N1 influenza vaccine in healthy Japanese adults.Influenza serological studies to inform public health action: best practices to optimise timing, quality and reporting.2009 A(H1N1) seroconversion rates and risk factors among the general population in Vientiane Capital, Laos.Kinetics of neutralizing antibodies in patients naturally infected by H5N1 virus.Multiplex evaluation of influenza neutralizing antibodies with potential applicability to in-field serological studies Association between antibody titers and protection against influenza virus infection within households Serologic assays for influenza surveillance, diagnosis and vaccine evaluation.Regulatory science accelerates the development of biotechnology drugs and vaccines by NIFDC Development of a neutralization assay for influenza virus using an endpoint assessment based on quantitative reverse-transcription PCR Serological Evidence and Risk Factors for Swine Influenza Infections among Chinese Swine Workers in Guangdong Province.Overview of Serological Techniques for Influenza Vaccine Evaluation: Past, Present and Future.Accelerating Influenza Research: Vaccines, Antivirals, Immunomodulators and Monoclonal Antibodies. The Manufacture of a New Wild-Type H3N2 Virus for the Human Viral Challenge Model International Laboratory Comparison of Influenza Microneutralization Assays for A(H1N1)pdm09, A(H3N2), and A(H5N1) Influenza Viruses by CONSISE Randomized, controlled trial of high-dose influenza vaccine among frail residents of long-term care facilities.Relationship between haemagglutination inhibition titre and immunity to influenza in ferrets.Serological evidence of H9N2 avian influenza virus exposure among poultry workers from Fars province of Iran.Standardization of Hemagglutination Inhibition Assay for Influenza Serology Allows for High Reproducibility between Laboratories.

P2860

Q26700365-9BD65B2A-2A1A-49CD-9A56-47DE81087EB7 Q26748397-CA33D0A8-5A6D-4ABE-842F-72B0971B62E1 Q26783844-251B7AE5-E217-4924-8E4F-71C419F29D4E Q27000896-11F44D26-A439-40AF-B009-6F3BB350DA18 Q28075317-F19DAB42-D3B6-4D69-95CC-502CB9DCE18E Q28751886-C4BA856F-FC8D-4857-A3D0-561ED6B43126 Q30000948-DCDA0956-754A-4FAD-AD3A-617C864A9C99 Q30210342-8D720199-7A47-41B8-931A-074A99541597 Q30223476-7FDA9ADF-E8B0-4268-A158-0ED87957E337 Q30226546-BCFA72E2-13E3-425C-B59E-B1C768CF87B0 Q30368239-D082C1B2-2589-45AF-9927-CF967877DAE2 Q30368645-00A3EBE4-8FD1-4FB6-B98F-81B331C9508B Q30374662-8E0DFA94-FBAE-48F8-B76C-76551019E6BA Q30375314-B3C64BA3-EC50-46D0-9876-FD9B9D24DD63 Q30382921-8534F795-61AE-48E6-B633-2733FE2B0161 Q30385397-084DAEE2-2B35-4440-98C4-E2988A37DAD8 Q30390554-4421D90D-4BEF-4835-BC34-604E0981880A Q30391853-F378D406-0CFA-4232-8D5F-7A070A998012 Q30401247-8B7D9908-826C-4FDC-800D-1EF80C170606 Q30401306-765E860A-4A5B-4A4A-9E3C-9E4D4B9F5580 Q30401611-2B68EEE9-031F-4A80-A021-B6761636BE9E Q30404184-C4185029-1E74-4039-B1A9-AC43EB10DA0B Q30407047-BE43BD26-C416-4A43-9D70-BB6D728B75CF Q30414384-E1A86AD1-DE78-420C-AF95-4AF94A83D42E Q30416214-C195D566-FD05-40A7-943C-8DDD32608266 Q30430052-66E835DC-B970-4B2D-B7B5-4FC9C843B277 Q33598702-DFC70E34-B290-4786-A149-19BA3EDA919A Q33914496-AEAD73DD-B004-4EB0-B6CB-00E88C3024D1 Q34106198-ECBA672D-F26D-4737-A038-0E665D7DFA4D Q34194336-B504A6C7-E51F-44EA-AF58-D43A38056FDC Q34289974-6AFB647A-307C-425B-9121-0262DD7F2CB5 Q34598349-E2E0E381-B440-499B-AA4E-A4D697D304A0 Q35643181-C5688C7C-0D4B-406F-B32B-021FF05EA26B Q35826733-DDEEAEF1-0527-4520-ABB9-72118FC94011 Q35892839-943AEAD5-67A4-4323-9180-3D8E73436FF8 Q35901999-52C3AD65-B4DF-413F-B830-BB4873D5FB5C Q35965224-87B5BCFB-8EF4-4BA9-8AEF-3A500A6049B9 Q36092328-B8AC4F22-6E1A-4220-8E33-5189BC804A13 Q36507964-8E395544-1684-4A2D-A61E-AE8E5A72978A Q36665657-4D4D89E4-A451-428F-A8C3-276DB7FC5ED1

P2860

Reproducibility of serologic assays for influenza virus A (H5N1).

http://www.wikidata.org/entity/Q33628688

description

2009 nî lūn-bûn

@nan

2009 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

name

Reproducibility of serologic assays for influenza virus A (H5N1).

@ast

Reproducibility of serologic assays for influenza virus A (H5N1).

@en

type

label

Reproducibility of serologic assays for influenza virus A (H5N1).

@ast

Reproducibility of serologic assays for influenza virus A (H5N1).

@en

prefLabel

Reproducibility of serologic assays for influenza virus A (H5N1).

@ast

Reproducibility of serologic assays for influenza virus A (H5N1).

@en

P1433

Q33628688-6E58501D-96EF-47C0-BC8F-CA6E2F787339

P1476

Q33628688-D5530EBF-CEB2-44F0-BF9F-3552DB41B009

P2093

Q33628688-1C102F93-2FD3-473F-BBA1-6008F1BC6594

Q33628688-308469B1-7301-4798-9F74-D7DCAF470131

Q33628688-57D2FBBF-91B2-4E5E-889C-B3CAE9B6D67A

Q33628688-5A0F80EE-1760-43C7-A33D-D5B5F6C76437

Q33628688-5AA75D6E-22DD-4263-9AFC-3837DBBA62CC

Q33628688-84856E5B-B44A-48FF-A3B7-15241326014C

Q33628688-917C04E5-91CC-41C5-89BC-D100722C80AC

Q33628688-95F7994C-F790-4199-BAE8-BD9A5304F0BF

Q33628688-E68C906F-4025-4979-9CCB-2120297FF065

P2860

Q33628688-17158A84-62D4-4A21-A009-5B4A1F301052

Q33628688-1E56F204-B244-4AB2-B522-3173C766605D

Q33628688-276A47AC-3D29-43C6-81F6-B0A7FB438DBA

Q33628688-35E5ED1E-8359-4122-B5AD-D5D4D9F42EDD

Q33628688-56D35A0B-83C7-417B-82B7-56D433A878A2

Q33628688-6FFEFB30-C750-46FD-80AD-FD6E17DB72A5

Q33628688-70EAED7E-1772-49AB-BA56-35ABEDA5B064

Q33628688-A5561249-66B7-429A-8ECD-5E33B952A612

Q33628688-A8BCA32B-757F-4F51-9A9E-B5FD8F873193

Q33628688-C7657D50-6427-4453-8095-A138249AF4D4

P304

Q33628688-B7A51842-4E67-4AFF-AD95-88CB6654B028

P31

Q33628688-617B84E6-AD3F-4472-8128-0E91FB15E4B6

P356

Q33628688-23A2FC4D-F5A7-4F46-8A28-57146A0BD1EB

P433

Q33628688-9D3823A3-D5C0-438B-AF2D-26E47BA778D8

P478

Q33628688-61FB9630-9438-42D8-B5D5-641420543136

P50

Q33628688-37005DF9-3D15-433B-8A73-752FEC693392

P577

Q33628688-D6FA787D-3A6E-4698-A436-E77CDEB58B7E

P5875

Q33628688-C8827354-CAEB-4E04-8CA0-20FC54EAC33A

P698

Q33628688-496D891A-6E33-4FA8-B5E2-7084F829258C

P921

Q33628688-2E17B90D-0B6F-423A-96C9-4BF4ABB357E4

P932

Q33628688-44146F1E-A761-4090-BEE9-91985B2B1CEB

P356

P1433

Emerging Infectious Diseases

P1476

Reproducibility of serologic assays for influenza virus A (H5N1).

@en

P2093

Alan Heath

http://www.w3.org/2001/XMLSchema#string

Diane Major

http://www.w3.org/2001/XMLSchema#string

Iain Stephenson

http://www.w3.org/2001/XMLSchema#string

Jerry P Weir

http://www.w3.org/2001/XMLSchema#string

John M Wood

http://www.w3.org/2001/XMLSchema#string

Katja Hoschler

http://www.w3.org/2001/XMLSchema#string

Maria C Zambon

http://www.w3.org/2001/XMLSchema#string

Robert W Newman

http://www.w3.org/2001/XMLSchema#string

Wang Junzi

http://www.w3.org/2001/XMLSchema#string

P2860

Evolution of H5N1 avian influenza viruses in Asia

Safety and antigenicity of non-adjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a randomised trial of two potential vaccines against H5N1 influenza.

Detection of antibody to avian influenza A (H5N1) virus in human serum by using a combination of serologic assays.

Testing human sera for antibodies against avian influenza viruses: horse RBC hemagglutination inhibition vs. microneutralization assays.

Determinants of immunity to influenza infection in man.

Rapid focus reduction neutralization test of influenza A and B viruses in microtiter system.

Detection of anti-H5 responses in human sera by HI using horse erythrocytes following MF59-adjuvanted influenza A/Duck/Singapore/97 vaccine.

Amount and avidity of serum antibodies against native glycoproteins and denatured virus after repeated influenza whole-virus vaccination.

The use of correlates of immunity in European Union licensing of influenza vaccines.

Sialic acid receptor specificity on erythrocytes affects detection of antibody to avian influenza haemagglutinin.

P304

1252-1259

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3201/EID1508.081754

http://www.w3.org/2001/XMLSchema#string

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

15

http://www.w3.org/2001/XMLSchema#string

P50

Jacqueline M. Katz

P577

2009-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

26809613

http://www.w3.org/2001/XMLSchema#string

P698

19751587

http://www.w3.org/2001/XMLSchema#string

P921

reproducibility

P932

2815968

http://www.w3.org/2001/XMLSchema#string